€12.10
1.18% today
Madrid, Aug 26, 05:38 pm CET
ISIN
ES0171996087
Symbol
GRF

Grifols Stock price

€12.10
-0.35 2.77% 1M
+2.48 25.75% 6M
+2.95 32.21% YTD
+2.52 26.28% 1Y
-0.33 2.62% 3Y
-11.16 47.98% 5Y
-5.81 32.45% 10Y
+9.55 375.25% 20Y
Madrid, Closing price Tue, Aug 26 2025
-0.15 1.18%
ISIN
ES0171996087
Symbol
GRF
Industry

Key metrics

Basic
Market capitalization
€7.5b
Enterprise Value
€16.3b
Net debt
€8.8b
Cash
€822.1m
Shares outstanding
680.4m
Valuation (TTM | estimate)
P/E
27.8 | 15.4
P/S
1.0 | 1.0
EV/Sales
2.2 | 2.1
EV/FCF
20.4
P/B
1.5
Dividends
DPS
€0.00
Yield 1Y | 5Y
0.0% | 0.6%
Growth 1Y | 5Y
- | -100.0%
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
€7.4b | €7.6b
EBITDA
€2.3b | €1.9b
EBIT
€1.3b | €1.4b
Net Income
€297.5m | €542.3m
Free Cash Flow
€798.2m
Growth (TTM | estimate)
Revenue
9.3% | 6.0%
EBITDA
127.6% | 47.5%
EBIT
44.1% | 22.1%
Net Income
100.8% | 245.6%
Free Cash Flow
257.8%
Margin (TTM | estimate)
Gross
39.4%
EBITDA
31.0% | 25.5%
EBIT
17.8%
Net
4.0% | 7.1%
Free Cash Flow
10.7%
Financial Health
Equity Ratio
27.5%
Return on Equity
2.7%
ROCE
7.5%
ROIC
-
Debt/Equity
1.9
More
EPS
€0.4
FCF per Share
€1.2
Short interest
-
Employees
24k
Rev per Employee
€300.0k
Show more

Is Grifols a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Grifols Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Grifols forecast:

13x Buy
65%
5x Hold
25%
2x Sell
10%

Analyst Opinions

20 Analysts have issued a Grifols forecast:

Buy
65%
Hold
25%
Sell
10%

Financial data from Grifols

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
7,446 7,446
9% 9%
100%
- Direct Costs 4,514 4,514
8% 8%
61%
2,932 2,932
12% 12%
39%
- Selling and Administrative Expenses 1,212 1,212
4% 4%
16%
- Research and Development Expense 395 395
15% 15%
5%
2,309 2,309
128% 128%
31%
- Depreciation and Amortization 984 984
934% 934%
13%
EBIT (Operating Income) EBIT 1,325 1,325
44% 44%
18%
Net Profit 297 297
101% 101%
4%

In millions EUR.

Don't miss a Thing! We will send you all news about Grifols directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Head office Spain
CEO Nacho Abia
Employees 23,833
Founded 1940
Website www.grifols.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today